A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...
AbbVie (ABBV) filed a biologics license application with the US Food and Drug Administration for etentamig, a second-generation BCMA-directed bispecific antibody for adults with relapsed or refractory ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
The Phase 3 trial showed a 60% risk reduction on its progression-free survival measure; dosing began with one step-up dose, ...
4hon MSN
Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting
Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio (elranatamab), when used in an earlier-line setting against the hematological cancer.
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, today announced that it has received a Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer ...
Pfizer's 523-patient ELREXFIO trial met its primary endpoint in previously treated myeloma; comparative efficacy details and ...
Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ...
AbbVie announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager ...
Multiple Myeloma Symptoms, Treatment & Prognosis / blood cancer, Bone Lesions, Cancer in Younger Adults, Cassie ...
The International Myeloma Foundation formed a network aiming to expand access to clinical trials for people with myeloma.
Nearly half of patients with multiple myeloma experience pathological fractures, according to a retrospective analysis of 692 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results